Jazz Pharmaceuticals 报告 2023 年收入增长。 Jazz Pharmaceuticals reported a revenue growth in 2023.
Jazz Pharmaceuticals 报告称，2023 年收入强劲增长，达到 38 亿美元，同比增长 27%。 Jazz Pharmaceuticals reported strong revenue growth in 2023, reaching $3.8 billion with a 27% YoY increase. 肿瘤学收入超过 10 亿美元，GAAP 净利润转正为 4.148 亿美元，非 GAAP 调整后净利润增至 13 亿美元。 Oncology revenue surpassed $1 billion, GAAP net income turned positive at $414.8m, and non-GAAP adjusted net income increased to $1.3bn. 该公司预计 2024 年收入将在 4 亿至 42 亿美元之间。 The company expects 2024 revenue to be between $4.0-4.2bn. 预计将于 2024 年推出一系列后期催化剂，包括 zanidatamab 的滚动 BLA 提交。 A pipeline of late-stage catalysts, including zanidatamab's rolling BLA submission, is anticipated for 2024.